ModernMedicine Resource Center More Topics

Diabetes - Patient Care Challenges Resource Center

Telemonitoring reduces diabetes patients’ blood sugar levels
Telemonitoring reduces diabetes patients’ blood sugar levelsA pharmacist-led telemonitoring program reduced blood sugar levels in diabetics, according to a new study.
Portal provides diabetes genetic dataA new online library or knowledge portal, the Type 2 Diabetes Genetics Beta, has been launched to provide open-access searching of genetic and clinical information on type 2 diabetes.
FDA approves long-acting insulin drugsFDA approved Tresiba (insulin degludec injection, Novo Nordisk) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection, Novo Nordisk) for the treatment of diabetes mellitus.
FDA warns of joint pain for DPP-4 diabetes drugs
FDA warns of joint pain for DPP-4 diabetes drugsFDA warned this week that several leading drugs for type 2 diabetes may cause severe and disabling joint pain. FDA said that sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain, and added a new Warning and Precaution about this risk to the labels of all dipeptidyl peptidase-4 (DPP-4) inhibitors.
FDA approves Synjardy for type 2 diabetesFDA has approved empagliflozin and metformin hydrochloride (Synjardy, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company) tablets for the treatment of adults with type 2 diabetes.
New insulin drug to enter crowded marketNovo Nordisk is expected to find out in October whether FDA will approve its long-acting insulin Tresiba for sale in the US market. However, if approved, Tresiba faces growing competition from Sanofi, which markets the leading basal insulin Lantus along with Toujeo.
Diabetes drug may reduce Parkinson’s incidenceDiabetes patients taking rosiglitazone or pioglitazone had a 28 percent lower incidence of Parkinson's disease (PD) than people taking other treatments for diabetes who had never taken the glitazone (GTZ) drugs, according to a new study.
[BLOG]: Obesity drug safety review
[BLOG]: Obesity drug safety reviewIn this blog post, Robert Kyle of AdverseEvents compares the results of a postmarket survey of 3 obesity drugs.
"Smart" patch may eliminate need for insulin shots in diabeticsA new, painless “smart insulin patch” lowered blood glucose in a mouse model of type 1 diabetes for up to 9 hours, according to a study published in the Proceedings of the National Academy of Sciences.
  • 1
  • 2